• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi appoints Olivier Brandicourt CEO

Sanofi appoints Olivier Brandicourt CEO

February 23, 2015
CenterWatch Staff

Sanofi’s board of directors unanimously has appointed Olivier Brandicourt CEO.

Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as chairman of the board of management of Bayer HealthCare and member of the executive council of Bayer. Previously, Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups such as Parke-Davis/Warner-Lambert and Pfizer. Brandicourt was a member of Pfizer's global executive leadership team from 2010-2013. 

A physician by training, Olivier Brandicourt's career includes several senior positions in Europe, Canada and the U.S. As the head of various healthcare divisions, he has a broad range of experience and knowledge of the pharmaceutical industry and has led the launch of numerous new medicines and the completion of strategic acquisitions and integrations.

Serge Weinberg, chairman of the board of directors, Sanofi, said, "Sanofi undertook a rigorous selection process to identify the right person to lead Sanofi forward at an important time for our company. I am very pleased that Olivier Brandicourt will be the next CEO of Sanofi. Olivier Brandicourt's strong experience combined with his international profile, deep knowledge of U.S. and emerging healthcare markets and his capability to unite teams will provide new dynamism to Sanofi's strategy of diversification and innovation."

In agreement with his former employer, Brandicourt will start April 2, 2015.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing